Every APOE4 trial, readable.
Each trial from ClinicalTrials.gov, translated into plain English with our read on what it means for carriers. Free, no signup.
Every protocol translated from trial-speak into sentences a human reads once.
A verdict per trial: does your genotype get you in, keep you out, or change the risk.
Synced from ClinicalTrials.gov every day, so a closed trial never wastes your call.
1,329 of 1,329 APOE4 trials match — showing the first 60
China Cognition and Aging Study
This is a large observational study based in China, not a drug or treatment trial. Researchers are building a national database by following thousands of people over time, tracking who develops memory problems or dementia, collecting brain scans, blood samples, and genetic data. The goal is to understand how dementia unfolds in Chinese populations. There is no Phase designation because nothing is being tested for approval — this is research groundwork.
Study to Evaluate the Efficacy and Safety of KDS2010 in Patients With Alzheimer's Disease With Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease
This trial is testing KDS2010, an experimental oral drug taken once daily, in people who have early Alzheimer's-related memory problems — either mild cognitive impairment or mild dementia confirmed by amyloid PET scan. Researchers are comparing two doses against a placebo to see whether it improves cognition, daily functioning, and biomarkers over 24 weeks. This is a Phase 2a trial, meaning it is an early test of whether the drug works and is safe — not proven or approved.
Is the CRP-Albumin-Lymphocyte (CALLY) Index Effective in Predicting Postoperative Delirium in Geriatric Patients Undergoing Hip Fracture Surgery
This study is testing whether a simple blood-test index called the CALLY Index, which combines three routine lab values, CRP, albumin, and lymphocyte count, can predict which elderly hip fracture patients will develop delirium after surgery. It is an observational study, not a treatment trial, meaning researchers are watching and measuring rather than giving any new therapy. Details on formal phase designation are not provided.
Comparison of Two Non-invasive Neuromodulation Techniques as Synergistic Therapy to Cognitive Stimulation in Amnestic Mild Cognitive Impairment (aMCI)
This trial is testing two types of non-invasive brain stimulation — repetitive transcranial magnetic stimulation (rTMS) and transcranial direct current stimulation (tDCS) — each paired with structured cognitive exercises, in people with amnestic mild cognitive impairment. Researchers want to see which combination best supports memory and brain function. This is a Phase NA (feasibility or exploratory) trial, meaning it is designed to gather early data, not to prove a treatment works definitively.
Intravenous Infusion of Umbilical Cord Blood as an Adjunctive Treatment for Alzheimer's Disease
This trial is testing whether infusing stem-like cells from donated umbilical cord blood — on top of a standard Alzheimer's drug — is safe and shows early signs of benefit in people with mild to moderate Alzheimer's. It is an Early Phase 1 trial, meaning the primary goal is safety and finding the right dose, not proving the treatment works. Thirty patients are divided into two dose groups and one placebo group, then followed for six months.
Predicting Pre-dementia
This observational study is testing whether a multimodal prediction model — combining genetic risk scores, blood biomarkers, health record data, and wearable device readings — can accurately forecast who will progress to early MCI within two years. There is no drug or treatment involved. It is observational, meaning researchers are watching and measuring, not intervening. Think of it as a sophisticated early-warning system study.
Sleep Impairment in Subjects at Risk of Developing Alzheimer's Disease
This study is observing whether poor sleep is linked to cognitive decline in people at early risk of Alzheimer's. Participants undergo sleep studies, cognitive testing, and biomarker checks — no experimental drug is involved. It is a non-interventional, observational study, meaning researchers are watching and measuring, not treating. The goal is to understand whether sleep problems predict or accelerate cognitive decline, which could eventually point toward earlier intervention.
The Effects of Social Isolation and Social Interaction on the Risk of Dementia Progression and Brain Function in SCD (Subjective Cognitive Decline, SCD)
This trial is studying how social isolation and social interaction affect the brain and the risk of progressing from subjective cognitive decline to more serious memory problems. Researchers will use observational studies and a randomized controlled trial to track participants over time and test whether staying socially connected protects brain function. The phase is unspecified, meaning it is exploratory research rather than a standard drug-testing trial.
Study on Biomarkers for Early Diagnosis of Alzheimer's Disease
This is an observational study based in China that is tracking elderly people over five years to identify early biological markers of Alzheimer's disease. Researchers are collecting blood, genetic, and brain imaging data across a range of participants — from cognitively normal to diagnosed AD — hoping to build better early-detection tools and a model that predicts five-year risk. No phase is listed because no drug or device is being tested.
Passive Sensor Identification of Digital Biomarkers to Assess Effects of Orally Administered Nicotinamide Riboside
This trial is testing whether a supplement called nicotinamide riboside (a form of vitamin B3) produces measurable changes in brain energy metabolism in people with mild cognitive impairment or mild Alzheimer's dementia. Researchers are using a passive home sensor device to track digital biomarkers — things like sleep, movement, and breathing patterns — rather than clinic visits alone. The phase is unspecified, so the scale and stage of testing are unclear from the available information.
Health Behavior Change in Midlife Adults at Risk for Alzheimer's Disease
This trial tests two versions of a healthy-living education program aimed at helping middle-aged adults make lasting lifestyle changes — better diet, more physical activity, stress management, and mental engagement. Researchers want to know which approach works better for sustaining those changes over time. It is a Phase NA (non-drug, behavioral) study, meaning it is testing whether the program works, with no experimental medication involved.
Brain Research Assessing Impacts of Neurophysiological Processing Speed Training in Veterans
This pilot study is testing whether EEG-guided alpha neurofeedback training and visual attention exercises can improve processing speed and daily functioning in older veterans with a history of mild traumatic brain injury. Researchers will measure brain activity before and after training to see how it affects cognitive performance. This is a Phase NA feasibility study — it is exploratory, not a definitive test of whether the approach works.
Transcranial Pulse Stimulation of the Brain
This trial is testing a device called transcranial pulse stimulation, or TPS, which delivers gentle ultrasound-like pulses to specific brain regions. Researchers want to see whether it improves cognitive function and changes brain structure in healthy older adults and people with mild dementia. This is a Phase NA, meaning it is a small pilot study of about 20 people — early-stage work to see whether the approach is worth pursuing further, not a proven treatment.
Feasibility of Using the Gatorade Sports Science Institute (GSSI) Labs App for Hydration Related Outcomes
This study tests whether a Gatorade-branded smartphone app can reliably collect hydration data from everyday people at home. Participants use the app alongside a wearable fitness tracker and a bathroom scale. There is no assigned phase — this is a feasibility study, meaning researchers are simply checking whether the app works as a research tool, not testing a medical treatment.
Analyzing the Benefits of Using SYMPTOMS-JIT for in Vivo Exposure in Anxiety Disorders
This trial tests whether adding a smartphone-based sensor tool called SYMPTOMS-JIT to standard cognitive behavioral therapy with in-person exposure exercises improves outcomes for people with anxiety disorders like phobias, panic disorder, and social anxiety. It is a Phase N/A trial, meaning it is studying a behavioral intervention rather than a drug — focused on whether this tech-assisted therapy works and how patients and therapists feel about it.
Validation of a Digital Intervention to Rehabilitate Cognitive Resources
This trial is testing RICORDO, a digital app that adapts cognitive rehabilitation exercises to each person's ability level. Researchers want to know whether it improves overall thinking and memory skills better than standard paper-and-pencil rehabilitation. It enrolls people with subjective memory complaints, mild cognitive impairment, or mild dementia. This is a Phase NA trial, meaning it is a validation or feasibility study rather than a standard efficacy phase.
An Observational Study on Lecanemab Treatment for Early Alzheimer's Disease
This observational study is watching people already receiving lecanemab — a drug approved for early Alzheimer's — to see whether blood-based biomarkers can accurately track how well the drug is clearing amyloid plaques from the brain, compared to PET scans. No one is being randomly assigned to treatment. It has no specified phase because it is not a drug trial — it is a real-world data collection study.
An Exploratory Study to Confirm Efficacy of Modified Deep Cervical Lymphovenous Anastomosis (LVA) in Alzheimer's Disease/ Parkinson's Disease
This trial is testing a surgical procedure called deep cervical lymphovenous anastomosis — a technique that connects lymphatic vessels to veins in the neck — to see if it can improve the brain's ability to clear out toxic proteins like amyloid and tau in Alzheimer's, or alpha-synuclein in Parkinson's. The idea is that aging lymphatic vessels drain poorly, letting those proteins build up. This is a Phase N/A exploratory study, meaning it is early-stage and intended to gather initial evidence, not a proven treatment.
Using the EHR to Advance Genomic Medicine Across a Diverse Health System
This trial is testing whether small prompts built into the electronic health record (EHR) — called behavioral nudges — can get more doctors and patients to pursue genetic testing for a range of conditions, including Alzheimer's disease and Parkinson's. It is a Phase NA pragmatic trial, meaning it is testing a delivery system, not a drug or treatment. The goal is to figure out whether smart EHR design can make genomic medicine routine.
NYSCF Scientific Discovery Biobank
This is a biobank study, not a treatment trial. NYSCF is collecting blood, skin, or saliva samples from people with various diseases — including Alzheimer's — as well as healthy volunteers. Those samples get converted into stem cells, studied in the lab, and stored for future research. There is no phase because no drug or device is being tested. It is infrastructure for science, not a clinical intervention.
Cohort of Patients with Alzheimer's Disease and Their Families.
This French observational study follows family clusters over two years: one person with mild-to-moderate Alzheimer's, their caregiver, and at least one first-degree relative. No treatment is given. Researchers are tracking blood biomarkers, risk factors, and caregiver wellbeing to see whether a larger study is feasible. Think of it as groundwork — gathering data, not testing a drug or therapy.
Lecanemab for Early Onset Familial Alzheimer's Disease
This observational study is giving lecanemab, an anti-amyloid antibody drug, to people under 65 who already have MCI or mild Alzheimer's and a family history of the disease. Researchers will track cognition, brain scans, and blood markers over 18 months, and do whole genome sequencing to see how genetic factors affect how well the drug works. Phase is unspecified, so this is exploratory rather than a large confirmatory trial.
Dyadic Personalized Home-Based Activity Program for Mild-to-Moderate Dementia Patients Post-Discharge
This trial tests whether a structured activity program — designed together with family caregivers before hospital discharge and then carried out at home for 12 weeks — can reduce behavioral and psychological symptoms in people with mild-to-moderate dementia. Think agitation, anxiety, and mood changes. It is a Phase NA randomized study, meaning it is evaluating effectiveness of a behavioral approach, not a drug. Details on the sponsoring institution are limited.
Motion-based Interactive Technology for Improved Quality of Life in Individuals With Cognitive Impairment
This trial is testing whether virtual cycling, pedaling a stationary bike while watching an interactive film, can improve quality of life, physical fitness, and social and cognitive engagement in nursing home residents with cognitive impairment. It is a Phase NA study, meaning it is evaluating a non-drug technology intervention rather than a medication, so it is focused on real-world usefulness rather than drug safety or efficacy in the traditional sense. Details on the full protocol are somewhat limited.
Analysis of 18F-XTR006 PET Imaging in Cognitively Normal Subjects, and Patients With MCI and AD
This trial is testing a new PET imaging agent called XTR006, which is injected before a brain scan to help detect tau tangles — a hallmark of Alzheimer's damage — in people who are cognitively normal, have mild cognitive impairment, or have Alzheimer's disease. It is a Phase 3 trial, meaning researchers are evaluating how accurately this imaging tool identifies tau in the brain compared to a reference standard. It is a diagnostic tool, not a treatment.
Instant Message-delivered Personalised Acceptance and Commitment Therapy (IMPACT) for Neuropsychiatric Symptoms in Persons With Mild Cognitive Impairment
This trial is testing whether an automated therapy program delivered by instant message on a smartphone can help people with mild cognitive impairment manage neuropsychiatric symptoms like anxiety, depression, and irritability. It uses Acceptance and Commitment Therapy principles, adapted for delivery by text or voice message. This is a Phase N/A trial, meaning it is focused on testing feasibility and early effectiveness rather than being a late-stage confirmatory study.
Natural History and Longitudinal Clinical Assessments in NCL / Batten Disease, the International DEM-CHILD Database
This is an observational registry study tracking how Neuronal Ceroid Lipofuscinosis (NCL), also called Batten Disease, progresses over time. Researchers collect medical records, questionnaires, and clinical exam data to understand how motor skills, language, cognition, seizures, vision, and behavior change. No new treatment is given. Because no phase is listed, this is a data-gathering effort, not a drug or device trial.
Pilot Study of a Brain Health Program in Senior Centers
This pilot study is testing a behavioral program called My Healthy Brain, delivered at senior centers, for older adults who notice memory slipping but do not have dementia. It is not measuring whether the program prevents Alzheimer's — it is checking whether the program is feasible, acceptable, and runs as intended. This is a Phase NA pilot, meaning it is early-stage groundwork, not a test of effectiveness yet.
Investigating if a Stronger tDCS Intensity is More Effective for Improving Naming Ability in People Living With Alzheimer's Disease
This trial tests whether a higher-intensity brain stimulation technique called tDCS — which delivers a mild electrical current through the scalp — improves word-finding ability in people with Alzheimer's disease when used alongside naming exercises. Researchers are comparing a standard dose of 2 milliamps against a stronger 4 milliamp dose to see which works better. This is a Phase NA study, meaning it is an exploratory trial focused on optimizing how the technique is applied, not a large-scale effectiveness study.
Tele-Savvy for Latino Caregivers
This trial is testing a culturally adapted, Spanish-language version of an online caregiver education program called Tele-Savvy, designed specifically for Latino caregivers of people with Alzheimer's or related dementias. It measures whether the program reduces caregiver stress, depression, and feelings of being overwhelmed. This is a Phase NA early-stage study — researchers are checking whether the adapted program is feasible and shows early signs of helping, not a large-scale proof of effectiveness.
Omics Sciences for the Identification of Pathogenetic Mechanisms and Biomarkers in Neurodegenerative Diseases
This study collects genetic, protein, and metabolic data from people with neurodegenerative diseases — including Alzheimer's, Parkinson's, ALS, FTD, and MCI — to look for biological patterns that might one day improve diagnosis or monitoring. It is an observational research study, not a treatment trial. No drug or intervention is being tested. Details on specific methods and enrollment criteria are limited so far.
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
This trial is testing KarXT plus KarX-EC, a combination drug approach aimed at improving cognition in people who already have mild to moderate Alzheimer's disease. Researchers are measuring whether it actually helps thinking and memory compared to a placebo. This is a Phase 3 trial, meaning it has already passed early safety testing and is now in a large, definitive study to see whether the treatment works well enough to support approval.
Validation of an Alzheimer's Disease Marker by Fecal Assay of Amyloid Peptides and Tau Proteins
This trial is testing whether Alzheimer's-related proteins — amyloid and tau — can be detected in stool samples. The idea is that the brain may clear these toxic proteins through the gut, making a simple fecal test a possible early diagnostic tool. This is a validation study, not a treatment trial, so it is focused on proving whether the test works, not on any therapy. Details on phase are not specified.
Cognitive Vulnerability to Stress in Individuals at Risk for Alzheimer's Disease
This study is testing whether stress hormones and genes linked to Alzheimer's risk predict how much a brief social stress experience affects memory and thinking in people with mild cognitive impairment. Researchers will also track whether those stress responses predict cognitive decline and changes in Alzheimer's biomarkers over two years. This is a Phase NA observational-style study — it is measuring and monitoring, not treating.
A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease
This trial is testing ALN-HTT02, an experimental drug designed to reduce the harmful huntingtin protein that drives Huntington's disease. Researchers are measuring safety, tolerability, and how the drug behaves in the body after single or repeated doses. It is a Phase 1 trial, meaning the primary goal is to establish that the drug is safe in humans — it is not yet proven or approved for any use.
A Culturally Adapted Decision Aid Intervention to Support Chinese American Dementia Caregivers in Feeding-Related Decisions
This pilot study tests a culturally adapted decision-support tool to help Chinese American family caregivers navigate the choice between tube feeding and hand feeding for a loved one with moderate or advanced dementia. It does not test a drug or medical treatment. Phase NA means this is exploratory research focused on usability and feasibility, not on proving a clinical outcome yet. Details beyond the pilot design are limited so far.
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
This Phase 2 trial is testing remternetug, an anti-amyloid antibody given by injection, in people who carry a rare genetic mutation (in APP, PSEN1, or PSEN2) that causes early-onset familial Alzheimer's disease. Researchers want to see whether the drug slows or prevents amyloid buildup in the brain, measured by PET scans and spinal fluid markers. Phase 2 means the drug is still being studied for effectiveness and safety — it is not approved.
Effects of a Computerised Cognitive Stimulation Versus Stimulating Leisure Activities
This trial compares two non-drug approaches for older adults with mild or subjective cognitive impairment: a personalized computerized cognitive stimulation program delivered through primary care, versus structured leisure activities. Researchers are measuring effects on memory, thinking skills, daily functioning, and mood. It is a Phase NA trial, meaning it is comparing two active interventions rather than testing a new drug or device for safety and efficacy in the traditional sense.
Transcranial Magnetic Stimulation Treatment for Alzheimer's Disease
This trial is testing whether repetitive Transcranial Magnetic Stimulation (rTMS) — a non-invasive device that briefly alters brain activity using magnetic pulses — can improve memory and brain-network function. Participants receive 20 sessions of either real or sham (inactive) rTMS over several weeks, with memory tests and MRI scans measuring the results. This is an Early Phase 1 study, meaning researchers are still exploring basic effects and safety in a small group.
Effects of Dexmedetomidine in Patients With Agitated Delirium in Palliative Care
This trial is testing dexmedetomidine, a sedative drug, to manage severe agitated delirium in patients near the end of life receiving palliative care. Researchers want to find the right dose, confirm it is practical to give subcutaneously outside a monitored hospital setting, and get an early read on whether it works. This is a Phase 1/2 trial, meaning it is focused on safety and dosing, not yet a proven or approved approach.
Music-Based Interventions, Aging, Alzheimer's Disease
This trial is testing whether singing in a choir improves hearing, communication, and emotional well-being in older adults who may be at higher risk for dementia. Participants are randomly assigned to either a choir group or a group music listening program. It is a Phase NA behavioral study, meaning it is evaluating real-world effects of an activity, not a drug or device. Details on sample size and duration are limited in the source.
Evaluation of The Relationship Between Perioperative Hypothermia and Emergence Agitation
This study looks at whether patients who get too cold during surgery (perioperative hypothermia) are more likely to wake up confused or agitated afterward (called emergence agitation). Researchers will track body temperature and use a sedation scale to see if there is a connection. This is an observational study — no experimental drug or device is being tested, just a relationship being measured in surgical patients.
Sense4Safety Intervention
Sense4Safety is a behavioral intervention using in-home sensors and machine learning to detect rising fall risk in real time, then connecting older adults with a coach to act on that risk. This Phase 1 trial enrolls people aged 65 and older who have mild cognitive impairment. Phase 1 here is about early safety and feasibility testing, not a proven or approved program.
Remotely Supervised tDCS+ for Complex Attention in mTBI (Cognetric)
This trial tests whether a non-invasive brain stimulation technique called tDCS, delivered at home and combined with cognitive training exercises, can improve attention and concentration in Active Duty Service Members and Veterans who have had a mild traumatic brain injury. Half of participants get real stimulation, half get a placebo version. It is a Phase NA study, meaning it is a controlled clinical trial focused on measuring effectiveness and brain changes, not a standard drug approval phase.
Cannabidiol Medication Intervention Trial
This trial is testing whether cannabidiol (CBD) capsules can safely reduce agitation in people who already have Alzheimer's disease. Agitation — restlessness, verbal outbursts, aggression — is one of the hardest symptoms for caregivers to manage. It is a Phase 2 trial, meaning researchers are still gathering evidence on whether it works and whether it is safe. Participants take either CBD or a placebo in a crossover design, so everyone tries both.
Effect of Cervical Lymphaticovenous and Lymph Node-to-Vein Anastomosis in Patients With Intracranial Lymphatic Circulation Disorder
This trial is testing a surgical procedure called lymphaticovenous anastomosis — tiny connections made between lymphatic vessels and veins in the neck — to see whether it improves brain waste clearance and cognitive function in people with Alzheimer's disease. It is a Phase NA study, meaning this is early exploratory work assessing whether the procedure is feasible and shows any effect, not yet proven or approved.
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
This trial is testing KarXT plus a new extended-release version called KarX-EC — a non-opioid, non-antipsychotic drug combination — to see whether it reduces agitation in people with Alzheimer's disease. Agitation is one of the most distressing symptoms for both patients and caregivers. This is a Phase 3 trial, meaning researchers are now testing whether it works well enough and is safe enough for potential approval.
AusCADASIL: An Australian Cohort of CADASIL
This study is building a long-term registry of Australians with CADASIL, a rare inherited condition that damages small blood vessels in the brain. Researchers will track symptoms, brain scans, blood markers, genetics, and cognitive testing over time to better understand how the disease progresses. This is an observational cohort study, not a treatment trial, so no drugs or interventions are being tested.
A rTMS and Virtual Reality Based Cognitive Rehabilitation Program for MCI
This trial is testing whether combining brain stimulation (rTMS) with immersive virtual reality cognitive training improves thinking, mood, daily functioning, and quality of life in people already diagnosed with Mild Cognitive Impairment. Participants are assigned to no treatment, rTMS alone, or rTMS plus VR training over two weeks, then followed for three months. This is a Phase NA interventional study — it is evaluating effectiveness of a combined non-drug approach, not a standard drug trial.
Exploration of an Online Education Program to Support Caregivers' Knowledge Transfer
This trial tests an online teaching method called Structured Retrieval Practice to help family caregivers better understand and manage the behavioral and psychological symptoms of dementia. The question is whether this educational approach helps caregivers apply what they learn to real-life situations. This is a Phase 1 trial, meaning it is an early-stage test of feasibility and approach, not a proven or approved intervention.
miR-342-5p/AnkG Pathway in Early AD Synaptic Dysfunction
This study is collecting blood samples, and optionally cerebrospinal fluid, from people with early Alzheimer's and healthy controls. Researchers want to know whether a specific molecular pathway (miR-342-5p/AnkG) shows up in body fluids and could serve as an early detection signal. This is not a drug trial — it is a biomarker discovery study, meaning researchers are building scientific groundwork, not testing a treatment.
The Clinical Study of Synaptic Plasticity-based Lencanumab for the Treatment of Early Alzheimer's Disease
This trial is testing lecanemab, an FDA-approved anti-amyloid antibody drug, against standard dementia medications in people with early Alzheimer's disease. The focus is on understanding how lecanemab affects synaptic function and brain network activity, using brain scans, PET imaging, and fluid biomarkers. The phase is unspecified, meaning this reads more like an observational or mechanistic study than a standard efficacy trial — it is not testing a new drug, but studying how an approved one works.
Warmth and Transcutaneous Electrical Nerve Stimulation (TENS) in Improving Cognitive Functions in People with Dementia
This trial tests whether a special hat that delivers both gentle warmth and mild electrical stimulation (TENS) to acupuncture points on the head can improve thinking and behavior in people with mild to moderate dementia. Participants are assigned to one of five versions of the hat — ranging from full warmth-plus-TENS to a control with neither. Phase NA means this is a standalone study design, not part of the standard drug-approval pipeline.
Repetitive Transcranial Magnetic Stimulation in Frontotemporal Lobar Degeneration
This trial is testing repetitive transcranial magnetic stimulation, or rTMS, in people diagnosed with frontotemporal dementia or in healthy family members who may be at risk. Using a magnetic device held near the skull, researchers deliver brief pulses to stimulate brain activity. They want to know if it is safe, feasible, and whether it changes clinical or biological markers of the disease. This is a Phase NA trial, meaning it is exploratory rather than a standard efficacy-proving phase.
FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases
FLOWER is a virtual observational study — no treatment involved — that collects and organizes medical records from people living with rare diseases. Researchers use electronic health records, faxed documents, and lab data to build a standardized database. There is no assigned intervention. This is not a phase-numbered trial; it is a data registry designed to improve how rare disease outcomes are tracked over time.
The Application of an AI-driven Multimodal Predictive Model for Cognitive Impairment in Patients With Type 2 Diabetes Mellitus
This observational study is testing whether an AI-powered screening tool can detect early memory and thinking problems in people who have type 2 diabetes. Researchers will follow participants for 3 to 5 years, tracking blood sugar control alongside cognitive changes. There is no drug or treatment involved — just monitoring and testing. The phase is unspecified, meaning this is likely a feasibility or validation study, not a clinical treatment trial.
e-ALIGN: A Patient Portal-based Intervention to Align Medications With What Matters Most
This trial tests whether sending educational materials through a patient portal, followed by a pharmacist-led conversation, can help older adults with MCI or dementia safely reduce medications that may be risky for the brain. These are called CNS potentially inappropriate medications. It is a pilot study, meaning researchers are gathering early data on whether the approach is practical and promising, not yet proving it works at scale.
PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
This trial uses specialized PET imaging to measure brain inflammation in people with Alzheimer's disease, Parkinson's, ALS, MCI, and related conditions. Researchers are injecting three radioactive tracers to see whether enzymes called COX-1 and COX-2 are elevated in diseased brains compared to healthy ones. It is a Phase 1 trial, meaning the primary goal is safety and feasibility of the imaging method itself, not testing a treatment.
The Effects of Successful OSA Treatment on Memory and AD Biomarkers in Older Adults Study
This trial is testing whether successfully treating moderate-to-severe obstructive sleep apnea (OSA) in older adults improves memory and changes biological markers linked to Alzheimer's disease. Participants are randomly assigned to start OSA treatment now or wait three months, then followed for two years. It is a Phase NA trial — meaning it is studying a clinical question about existing devices, not testing a new drug for approval.
BID WM Digital Intervention in Aging
This trial is testing two digital brain-training apps — called Coherence and Worder — to see whether eight weeks of at-home use can improve working memory and inhibitory control in older adults, including those with mild cognitive impairment. It is a Phase NA study, meaning this is more of a feasibility and efficacy exploration than a late-stage drug trial. Participants do everything remotely, with check-ins at baseline, post-intervention, and six months later.
APOE4 trial pipeline
Where the trials sit in the development pipeline. Higher bars = more research underway.
Browse every APOE4 trial (1,329)
Explore the trials.
Browse APOE4-relevant Alzheimer’s trials by state or recruiting status, or start with our plain-English guide to joining one.
By state